Ilja K.
- Country
- Germany
- Department
- Klinik für Innere Medizin III
Research Overview
- Evaluation of Sequential Versus Up-Front Administration of Durvalumab, Tremelimumab, and Bevacizumab in Non-Resectable Hepatocellular Carcinoma
- Phase III Randomized Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE versus TACE Alone in Locoregional Hepatocellular Carcinoma
- Evaluation of Durvalumab and Bevacizumab as Adjuvant Therapy in High-Risk Hepatocellular Carcinoma Post-Curative Resection or Ablation
Data & Insights
Has run more than one trial at 41 of 104 partner sites.
Specializations
Liver Cancer Treatment
The investigator specializes in innovative therapeutic approaches for hepatocellular carcinoma (HCC), with particular emphasis on treating both resectable and non-resectable cases.
- Advanced Immunotherapy Combinations
- Targeted Biological Therapies
- Post-surgical Recurrence Prevention
Their research encompasses novel treatment strategies using immunotherapy agents in combination with anti-angiogenic treatments.
Interventional Oncology
Focuses on integrating transarterial chemoembolization (TACE) with systemic therapies for liver cancer treatment, exploring both sequential and concurrent treatment approaches.
- Combined Modality Treatment
- Locoregional Therapy
- Selective TACE Techniques
Investigates innovative approaches to optimize timing and sequencing of local and systemic treatments.
Clinical Innovation
Develops treatment strategies for unresectable liver cancer utilizing multiple therapeutic modalities, including dual immunotherapy combinations and targeted agents.
- Triple Therapy Approaches
- Risk Reduction Strategies
- Treatment Sequencing
Explores novel therapeutic combinations to improve outcomes in advanced liver cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.